Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06505603 · ClinicalTrials.gov registry record
PiMZ Longitudinal Cohort (PiMZ Logic)
A clinical trial of Alpha-1 Antitrypsin Deficiency and Emphysema or COPD, sponsored by Columbia University.
- Recruiting
- Registry status
- 80
- Enrollment target
- 5
- Study locations
NCT06505603 is a study of Alpha-1 Antitrypsin Deficiency and Emphysema or COPD that is actively recruiting participants, run by Columbia University. The registered enrollment target is 80 participants, below the 3,073-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06505603, a study of Alpha-1 Antitrypsin Deficiency and Emphysema or COPD, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 5
- Study locations
Study Summary
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being PiMZ. The purpose of this study in PiMZ heterozygous patients is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers pertinent to the PiMZ patient that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.
Conditions Studied
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California- Los Angeles - Los Angeles
Colorado
- National Jewish Health - Denver
Illinois
- University of Chicago - Chicago
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2029-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06505603
The ClinicalTrials.gov registry entry for NCT06505603 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,073-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (97% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT06505603 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06505603 about?
NCT06505603 is a clinical study titled "PiMZ Longitudinal Cohort (PiMZ Logic)". Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being PiMZ. The purpose of this study in PiMZ heterozygous patients is to examine the density of the lung as...
What is the current status of trial NCT06505603?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2025-05-30. Estimated completion is 2029-02.
What conditions does trial NCT06505603 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency, Emphysema or COPD.
Who is sponsoring clinical trial NCT06505603?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06505603 being conducted?
This trial has 5 study locations across Alabama, California, Colorado, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
Alpha-1 Research Registry
RECRUITING
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.